GlassScriptPhysician profile
Marinda L Benjamin
NPI 1356777171
$5,712.83
in general payments reported to CMS, 2019-2025
34 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $712 · 2023: $1,323 · 2024: $1,745 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,485.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,791.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $593.34 | 2023-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Novo Nordisk INC | $533.36 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $416.60 | 2022-2025 | |
| Abbott Laboratories | $391.99 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $312.55 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $252.18 | 2024-2025 | Veozah |
| Lilly USA, LLC | $191.04 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $117.62 | 2023-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $112.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.52 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.67 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $105.57 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $69.23 | 2023-2025 | |
| Corcept Therapeutics | $65.01 | 2025 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $60.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.59 | 2023-2025 | |
| Eisai INC. | $45.15 | 2025 | |
| Dexcom, INC. | $43.34 | 2022-2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $34.09 | 2024 | Sapien 3 Ultra Resilia |
| Teva Pharmaceuticals USA, INC. | $25.03 | 2021-2022 | |
| Lundbeck LLC | $23.18 | 2025 | Vyepti |
| Gilead Sciences, INC. | $22.45 | 2025 | |
| Esperion Therapeutics, INC. | $22.00 | 2024 | Nexletol |
| Mayne Pharma Commercial LLC | $21.56 | 2022 | |
| Mylan Specialty L.P. | $20.58 | 2024 | Yupelri |
| Amarin Pharma, INC. | $19.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.91 | 2022 | |
| Shield Therapeutics INC | $17.95 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.06 | 2025 | Zoryve |
| Tolmar, INC. | $14.00 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $13.11 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marinda Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.